These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 12425361

  • 1. Metabolic syndrome, diabetes and coronary heart disease.
    Haffner SM.
    Int J Clin Pract Suppl; 2002 Oct; (132):31-7. PubMed ID: 12425361
    [No Abstract] [Full Text] [Related]

  • 2. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus.
    Mojiminiyi OA, Abdella NA.
    Scand J Clin Lab Invest; 2007 Oct; 67(2):215-25. PubMed ID: 17366001
    [Abstract] [Full Text] [Related]

  • 3. The appropriateness of nicotinic acid derivative use in patients with the metabolic syndrome: insights from the ARBITER 2 study.
    Al-Shaer MH, Jerome WP.
    Am J Cardiol; 2006 Jul 15; 98(2):275-6. PubMed ID: 16828609
    [No Abstract] [Full Text] [Related]

  • 4. Cross-sectional study of complement C3 as a coronary risk factor among men and women.
    Onat A, Uzunlar B, Hergenç G, Yazici M, Sari I, Uyarel H, Can G, Sansoy V.
    Clin Sci (Lond); 2005 Feb 15; 108(2):129-35. PubMed ID: 15487975
    [Abstract] [Full Text] [Related]

  • 5. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes.
    Tong PC, Kong AP, So WY, Yang X, Ho CS, Ma RC, Ozaki R, Chow CC, Lam CW, Chan JC, Cockram CS.
    Diabetes Care; 2007 May 15; 30(5):1206-11. PubMed ID: 17259472
    [Abstract] [Full Text] [Related]

  • 6. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes.
    Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhi A.
    Int J Obes (Lond); 2007 Feb 15; 31(2):213-20. PubMed ID: 16755284
    [Abstract] [Full Text] [Related]

  • 7. The metabolic syndrome and its cardiovascular manifestations.
    Sánchez-Torres RJ, Delgado-Osorio H.
    Bol Asoc Med P R; 2005 Feb 15; 97(4):271-80. PubMed ID: 16599068
    [Abstract] [Full Text] [Related]

  • 8. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study.
    Buyken AE, von Eckardstein A, Schulte H, Cullen P, Assmann G.
    Eur J Cardiovasc Prev Rehabil; 2007 Apr 15; 14(2):230-6. PubMed ID: 17446801
    [Abstract] [Full Text] [Related]

  • 9. Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?
    Taskinen MR.
    Nutr Metab Cardiovasc Dis; 2006 Dec 15; 16(8):509-12. PubMed ID: 17071064
    [No Abstract] [Full Text] [Related]

  • 10. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM.
    Am J Cardiol; 2008 Dec 22; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract] [Full Text] [Related]

  • 11. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease.
    Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ.
    Diabetes Obes Metab; 2007 May 22; 9(3):218-32. PubMed ID: 17391148
    [Abstract] [Full Text] [Related]

  • 12. Inflammation, the metabolic syndrome and cardiovascular risk.
    Tracy RP.
    Int J Clin Pract Suppl; 2003 Mar 22; (134):10-7. PubMed ID: 12793593
    [Abstract] [Full Text] [Related]

  • 13. [Statin treatment in type 2 diabetes. Is it a must today?].
    Faust M.
    MMW Fortschr Med; 2003 Feb 27; 145(9):35-6. PubMed ID: 12666527
    [No Abstract] [Full Text] [Related]

  • 14. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J.
    Diabetes Obes Metab; 2007 Sep 27; 9(5):609-16. PubMed ID: 17697054
    [Abstract] [Full Text] [Related]

  • 15. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G.
    Am J Cardiol; 2008 Dec 22; 102(12A):28L-33L. PubMed ID: 19084087
    [Abstract] [Full Text] [Related]

  • 16. Serum adiponectin as a useful marker for metabolic syndrome in type 2 diabetic patients.
    Yun JE, Sull JW, Lee HY, Park E, Kim S, Jo J, Lee SJ, Kim SY, Choi YJ, Jee SH, Huh KB.
    Diabetes Metab Res Rev; 2009 Mar 22; 25(3):259-65. PubMed ID: 19214966
    [Abstract] [Full Text] [Related]

  • 17. The evidence for lipid lowering: type 2 diabetes and coronary heart disease risk.
    Townsend D, Davis R.
    Prof Nurse; 2004 Jun 22; 19(10):38-40. PubMed ID: 15233071
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Metabolic complications of obesity: inflated or inflamed?
    Chandalia M, Abate N.
    J Diabetes Complications; 2007 Jun 22; 21(2):128-36. PubMed ID: 17331862
    [Abstract] [Full Text] [Related]

  • 20. Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk.
    Smith SR.
    Obesity (Silver Spring); 2006 Jun 22; 14 Suppl 3():128S-134S. PubMed ID: 16931494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.